Evandro de Azambuja1, Lieveke Ameye2, Marie Diaz3, Sandrine Vandenbossche4, Philippe Aftimos5, Sara Bejarano Hernández5, Chao Shih-Li6, François Delhaye7, Christian Focan8, Nathalie Cornez9, Anita Vindevoghel10, Marc Beauduin11, Marc Lemort6, Marianne Paesmans2, Thomas Suter12, Martine Piccart-Gebhart5. 1. Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: evandro.azambuja@bordet.be. 2. Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. 3. Department of Oncology, Hôpital Ambroise Pare, Mons, Belgium. 4. Neuropsychologue CHIREC, Brussels, Belgium. 5. Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. 6. Department of Radiology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. 7. Cardiology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. 8. Department of Oncology, CHC-Clinique Saint-Joseph, Liege, Belgium. 9. Department of Oncology, CHU Tivoli - GOHH, La Louviere, Belgium. 10. Clinique Ste-Elisabeth, Namur, Belgium. 11. Department of Oncology, Hôpital de Jolimont, Haine St Paul, Belgium. 12. Swiss Cardiovascular Center, Inselspital, Bern University Hospital, Bern, Switzerland.
Abstract
BACKGROUND:Epirubicin-based chemotherapy improves the outcome of early breast cancer (BC) patients. However, cardiotoxicity remains an important side effect. METHODS: We re-consented node-positive BC patients enrolled in a phase III trial between 1988 and 1996 which compared six cycles oforal cyclophosphamide, methotrexate, fluorouracil (CMF) versus two epirubicin-cyclophosphamide regimens differing by the anthracycline cumulative dose [standard-dose epirubicin and cyclophosphamide (SDE) (8 × 60 mg/m(2)) and higher-dose epirubicin and cyclophosphamide (HDE) (8 × 100 mg/m(2))]. Eligible patients were those who were alive and free of disease and had no contra-indications to the proposed tests (cardiac evaluation). Cardiotoxicity was defined as asymptomatic systolic dysfunction (left ventricular ejection fraction (LVEF)< 50%, New York Heart Association (NYHA) Class I) or symptomatic heart failure (NYHA Class II-IV). Differences in cardiotoxicity between CMF and SDE/HDE were assessed using chi-square and Fisher Exact tests for binary variables and t-test and Wilcoxon test for continuous variables. RESULTS: Among the 777 patients, 20 cases of CHF were reported (CMF = 1, SDE = 5, HDE = 14; p < 0.001). Between September 2010 and June 2013, 82 patients (30%) out of 269 eligible patients accepted to participate in this substudy. Median follow-up was 18 years (range 15-24). Epirubicin-treated patients had significantly higher heart rate, more abnormal echocardiograms and LVEF by magnetic resonance imaging (MRI) compared to CMF-treated ones. A trend towards higher BNP was also observed in the SDE/HDE group (P = 0.08). No differences were observed in LVEF assessed by echocardiogram or troponin T levels. CONCLUSIONS:Participation rate in this substudy was lower than expected highlighting the complexity of re-calling patients several years after the initial BC diagnosis. After 18 years, epirubicin-treated patients had a lower LVEF by MRI, more abnormal echocardiograms, higher heart rates compared to patients treated with CMF. However, no major delayed cardiotoxicity was observed.
RCT Entities:
BACKGROUND:Epirubicin-based chemotherapy improves the outcome of early breast cancer (BC) patients. However, cardiotoxicity remains an important side effect. METHODS: We re-consented node-positive BC patients enrolled in a phase III trial between 1988 and 1996 which compared six cycles of oral cyclophosphamide, methotrexate, fluorouracil (CMF) versus two epirubicin-cyclophosphamide regimens differing by the anthracycline cumulative dose [standard-dose epirubicin and cyclophosphamide (SDE) (8 × 60 mg/m(2)) and higher-dose epirubicin and cyclophosphamide (HDE) (8 × 100 mg/m(2))]. Eligible patients were those who were alive and free of disease and had no contra-indications to the proposed tests (cardiac evaluation). Cardiotoxicity was defined as asymptomatic systolic dysfunction (left ventricular ejection fraction (LVEF)< 50%, New York Heart Association (NYHA) Class I) or symptomatic heart failure (NYHA Class II-IV). Differences in cardiotoxicity between CMF and SDE/HDE were assessed using chi-square and Fisher Exact tests for binary variables and t-test and Wilcoxon test for continuous variables. RESULTS: Among the 777 patients, 20 cases of CHF were reported (CMF = 1, SDE = 5, HDE = 14; p < 0.001). Between September 2010 and June 2013, 82 patients (30%) out of 269 eligible patients accepted to participate in this substudy. Median follow-up was 18 years (range 15-24). Epirubicin-treated patients had significantly higher heart rate, more abnormal echocardiograms and LVEF by magnetic resonance imaging (MRI) compared to CMF-treated ones. A trend towards higher BNP was also observed in the SDE/HDE group (P = 0.08). No differences were observed in LVEF assessed by echocardiogram or troponin T levels. CONCLUSIONS: Participation rate in this substudy was lower than expected highlighting the complexity of re-calling patients several years after the initial BC diagnosis. After 18 years, epirubicin-treated patients had a lower LVEF by MRI, more abnormal echocardiograms, higher heart rates compared to patients treated with CMF. However, no major delayed cardiotoxicity was observed.
Authors: Seulggie Choi; Kyae Hyung Kim; Kyuwoong Kim; Jooyoung Chang; Sung Min Kim; Seong Rae Kim; Yoosun Cho; Gyeongsil Lee; Joung Sik Son; Sang Min Park Journal: Int J Environ Res Public Health Date: 2020-04-21 Impact factor: 3.390
Authors: Tienush Rassaf; Matthias Totzeck; Johannes Backs; Carsten Bokemeyer; Michael Hallek; Denise Hilfiker-Kleiner; Andreas Hochhaus; Diana Lüftner; Oliver J Müller; Ulrich Neudorf; Roman Pfister; Stephan von Haehling; Lorenz H Lehmann; Johann Bauersachs Journal: Clin Res Cardiol Date: 2020-05-13 Impact factor: 5.460
Authors: Jutta Bergler-Klein; Peter P Rainer; Markus Wallner; Marc-Michael Zaruba; Jakob Dörler; Armin Böhmer; Tamara Buchacher; Maria Frey; Christopher Adlbrecht; Rupert Bartsch; Mariann Gyöngyösi; Ursula-Maria Fürst Journal: Wien Klin Wochenschr Date: 2022-05-04 Impact factor: 2.275
Authors: Daniel Escutia-Reyes; José Javier Reyes-Lagos; José de Jesús Garduño-García; Gerardo Emilio-López-Chávez; Ángel Gómez-Villanueva; Adriana Cristina Pliego-Carrillo; Alexandra Estela Soto-Piña Journal: Sci Rep Date: 2021-07-14 Impact factor: 4.379
Authors: Carmen Bergom; Jason Rubenstein; J Frank Wilson; Aimee Welsh; El-Sayed H Ibrahim; Phillip Prior; Aronne M Schottstaedt; Daniel Eastwood; Mei-Jie Zhang; Adam Currey; Lindsay Puckett; Jennifer L Strande; Julie A Bradley; Julia White Journal: Front Oncol Date: 2020-10-16 Impact factor: 6.244